← board
SPRO
Spero Therapeuticsdistress 2/10 · well-funded / low risk$1.24-2%today-58% from 52w high
Infectious Disease 1
Lead: complicated urinary tract infection
Revenue
pre-revenue
Liquidity
$56M
Runway
—
Shares 1y
+3%
Price & events
-49.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-21.0%
1W
-42.3%
1M
-55.7%
3M
-49.2%
6M
-47.9%
1Y
-10.1%
2Y
-91.3%
5Y
-93.1%
All
Overview
- Market Cap
- $71.80M
- Volume
- 174.80K
- 52 Week Range
- $1.24 – $2.98
- Total Shares
- 57.90M
- Float Shares
- 46.38M
- Short %
- 5.97%
- % Held by Insiders
- 22.46%
- % Held by Institutions
- 16.16%
- RVOL
- 0.09x
- Beta
- 1.49
Pipeline stages · 1 programs
TBP-PI-HBr
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-04-22 | Phase 1 | TBP-PI-HBr | Healthy Participants | 39 | completed |
| 2025-01-27 | Phase 3 | TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets | Urinary Tract Infection, Acute Pyelonephritis | 1690 | completed |
Catalyst news & presentations · 11
- within 12 months from July 8, 2026regulatory submissionFiled (NDA/BLA)SP001 · IND filing for SP001SEC 8-K
- 2H 2026Guided 55%PDUFAPDUFAtebipenem HBr · Regulatory decision anticipatedSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-08partnershipSP001 · License agreement with Innovent for SP001.SEC 8-K
- second half of 2025enrollment completesecondaryPhase 3Tebipenem HBr · Enrollment completion in global PIVOT-PO trialSEC 8-K
- 2H 2025regulatory submissionFiled (NDA/BLA)tebipenem HBr · Planned FDA filing for tebipenem HBr for cUTISEC 8-K
- 2025-12-19partnershiptebipenem HBr · GSK NDA resubmission triggers $25M milestone payment expected in Q1 2026SEC 8-K
- 4Q 2024readoutPhase 1SPR720 · Topline results from BAL and drug-drug interaction studiesSEC 8-K
- 2024-10-29trial discontinuedSPR720 · Development program suspended due to efficacy and safety dataSEC 8-K
- 2024-10-29safety signalSPR720 · Three cases of reversible grade 3 hepatotoxicity at 1000 mg doseSEC 8-K
- 2024-08-05fda agreementSPR206 · FDA cleared IND for Phase 2 trial in HABP/VABPSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $4 (+223% upside) · 1 analysts
- 2025-01-30HC Wainwright & Co.Buy
- 2024-12-20Evercore ISI GroupOutperform → In-Line
- 2024-12-02HC Wainwright & Co.Buy
- 2024-11-18TD CowenBuy → Hold
- 2024-11-15Cantor FitzgeraldOverweight
- 2024-11-04HC Wainwright & Co.Buy
Competitors — complicated urinary tract infection
- none identified
Recent news
- 2026-07-21Spero Therapeutics Secures $105 Million Royalty Financing and Exclusive License for SP001 - Global Legal Chronicle
- 2026-07-20SPRO stock holds its ground on Spero Therapeutics financing and pipeline - Ad-hoc-news.de
- 2026-07-18Price to sales forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
- 2026-07-15Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice - GuruFocus
- 2026-07-14Spero Therapeutics (SPRO) Secures Exclusive License for IBI355 - GuruFocus
- 2026-07-14Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline - citybiz
- 2026-07-14Spero in-licenses Innovent’s antibody therapy (SPRO:NASDAQ) - Seeking Alpha
- 2026-07-14Spero Therapeutics (SPRO) Secures Exclusive License for SP001 De - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.